193 related articles for article (PubMed ID: 29880614)
1. ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.
Roberts KG; Janke LJ; Zhao Y; Seth A; Ma J; Finkelstein D; Smith S; Ebata K; Tuch BB; Hunger SP; Mullighan CG
Blood; 2018 Aug; 132(8):861-865. PubMed ID: 29880614
[No Abstract] [Full Text] [Related]
2. TKIs may be option for Ph-like ALL.
Cancer Discov; 2014 Dec; 4(12):1359-60. PubMed ID: 25477088
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
4. Establishment of MLL/AF4 transgenic mice with the phenotype of lymphoblastic leukemia or lymphoma.
Tamai H; Inokuchi K
J Nippon Med Sch; 2013; 80(5):326-7. PubMed ID: 24189350
[No Abstract] [Full Text] [Related]
5. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
6. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
Hu T; Ciccarelli BT
Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
[No Abstract] [Full Text] [Related]
7. ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis.
Jakobczyk H; Jiang Y; Debaize L; Soubise B; Avner S; Sérandour AA; Rouger-Gaudichon J; Rio AG; Carroll JS; Raslova H; Gilot D; Liu Z; Demengeot J; Salbert G; Douet-Guilbert N; Corcos L; Galibert MD; Gandemer V; Troadec MB
Leukemia; 2022 Feb; 36(2):549-554. PubMed ID: 34535762
[TBL] [Abstract][Full Text] [Related]
8. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
Chen YP; Lin HJ; Chen JS; Tsai MY; Hsieh HP; Chang JY; Chen NF; Chang KC; Huang WT; Su WC; Yang ST; Chang WC; Hung LY; Chen TY
Int J Cancer; 2014 Aug; 135(3):751-62. PubMed ID: 24382688
[TBL] [Abstract][Full Text] [Related]
9. ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.
Kantner HP; Warsch W; Delogu A; Bauer E; Esterbauer H; Casanova E; Sexl V; Stoiber D
Neoplasia; 2013 Nov; 15(11):1292-300. PubMed ID: 24339741
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-NTRK3 fusion.
Zhou K; Gong D; He C; Xiao M; Zhang M; Huang W
Mol Carcinog; 2023 Jul; 62(7):899-906. PubMed ID: 37036164
[TBL] [Abstract][Full Text] [Related]
11. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with
Frech M; Jehn LB; Stabla K; Mielke S; Steffen B; Einsele H; Metzelder SK; Neubauer A
Haematologica; 2017 Apr; 102(4):e160-e162. PubMed ID: 28057740
[No Abstract] [Full Text] [Related]
13. ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia.
Stoskus M; Vaitkeviciene G; Eidukaite A; Griskevicius L
Blood Cells Mol Dis; 2016 Mar; 57():30-4. PubMed ID: 26852652
[TBL] [Abstract][Full Text] [Related]
14. Mature B-cell acute lymphoblastic leukaemia associated with a rare MLL-FOXO4 fusion gene.
Lim L; Chen KS; Krishnan S; Gole L; Ariffin H
Br J Haematol; 2012 Jun; 157(6):651. PubMed ID: 22429121
[No Abstract] [Full Text] [Related]
15. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
[TBL] [Abstract][Full Text] [Related]
16. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
17. Clonal origins of ETV6-RUNX1⁺ acute lymphoblastic leukemia: studies in monozygotic twins.
Alpar D; Wren D; Ermini L; Mansur MB; van Delft FW; Bateman CM; Titley I; Kearney L; Szczepanski T; Gonzalez D; Ford AM; Potter NE; Greaves M
Leukemia; 2015 Apr; 29(4):839-46. PubMed ID: 25388957
[TBL] [Abstract][Full Text] [Related]
18. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
[TBL] [Abstract][Full Text] [Related]
19. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
Bell D; Ferrarotto R; Liang L; Goepfert RP; Li J; Ning J; Broaddus R; Weber RS; El-Naggar AK
Virchows Arch; 2020 Feb; 476(2):295-305. PubMed ID: 31423558
[TBL] [Abstract][Full Text] [Related]
20. ETV6-RUNX1-positive ALL may be driven by aberrant RAG activity.
Cancer Discov; 2014 Mar; 4(3):OF15. PubMed ID: 24596209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
